|
1
|
Macdonald TT and Monteleone G: Immunity,
inflammation, and allergy in the gut. Science. 307:1920–1925. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bouma G and Strober W: The immunological
and genetic basis of inflammatory bowel disease. Nat Rev Immunol.
3:521–533. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ardizzone S and Bianchi Porro G: Biologic
therapy for inflammatory bowel disease. Drugs. 65:2253–2286. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanauer SB: Inflammatory bowel disease:
epidemiology, pathogenesis, and therapeutic opportunities. Inflamm
Bowel Dis. 12:S3–S9. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Podolsky DK: Inflammatory bowel disease. N
Engl J Med. 347:417–429. 2002. View Article : Google Scholar
|
|
6
|
Rogler G and Andus T: Cytokines in
inflammatory bowel disease. World J Surg. 22:382–389. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Dieren JM, Kuipers EJ, Samsom JN,
Nieuwenhuis EE and van der Woude CJ: Revisiting the
immunomodulators tacrolimus, methotrexate, and mycophenolate
mofetil: their mechanisms of action and role in the treatment of
IBD. Inflamm Bowel Dis. 12:311–327. 2006.PubMed/NCBI
|
|
8
|
Xu CT, Meng SY and Pan BR: Drug therapy
for ulcerative colitis. World J Gastroenterol. 10:2311–2317.
2004.PubMed/NCBI
|
|
9
|
Sun Y, Xu W, Zhang W, Hu Q and Zeng X:
Optimizing the extraction of phenolic antioxidants from kudingcha
made from Ilex kudingcha C.J. Tseng by using response
surface methodology. Sep Sci Technol. 78:311–320. 2011.
|
|
10
|
Nishimura K, Fukuda T, Miyase T, Noguchi H
and Chen XM: Activity-guided isolation of triterpenoid acyl CoA
cholesteryl acyl transferase (ACAT) inhibitors from Ilex kudincha.
J Nat Prod. 62:1061–1064. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu F, Cai YZ, Sun M, Ke J, Lu D and Corke
H: Comparison of major phenolic constituents and in vitro
antioxidant activity of diverse kudingcha genotypes from Ilex
kudingcha, Ilex cornuta, and Ligustrum robustum.
J Agric Food Chem. 57:6082–6089. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thuong PT, Su ND, Ngoc TM, Hung TM, Dang
NH, Thuan ND, Bae K and Oh WK: Antioxidant activity and principles
of Vietnam bitter tea Ilex kudingcha. Food Chem.
113:139–145. 2009. View Article : Google Scholar
|
|
13
|
Chen ZY, Wong IY, Leung MW, He ZD and
Huang Y: Characterization of antioxidants present in bitter tea
(Ligustrum pedunculare). J Agric Food Chem. 50:7530–7535.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wong IY, He ZD, Huang Y and Chen ZY:
Antioxidative activities of phenylethanoid glycosides from
Ligustrum purpurascens. J Agric Food Chem. 49:3113–3119.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
She GM, Wang D, Zeng SF, Yang CR and Zhang
YJ: New phenylethanoid glycosides and sugar esters from
ku-ding-cha, a herbal tea produced from Ligustrum
purpurascens. J Food Sci. 73:C476–C481. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lau KM, He ZD, Dong H, Fung KP and But PP:
Anti-oxidative, anti-inflammatory and hepato-protective effects of
Ligustrum robustum. J Ethnopharmacol. 83:63–71. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pu F, Mishima K, Irie K, Egashira N,
Ishibashi D, Matsumoto Y, Ikeda T, Iwasaki K, Fujii H, Kosuna K and
Fujiwara M: Differential effects of buckwheat and kudingcha extract
on neuronal damage in cultured hippocampal neurons and spatial
memory impairment induced by scopolamine in an eight-arm radial
maze. J Health Sci. 51:636–644. 2005. View Article : Google Scholar
|
|
18
|
Kim JY, Jeong HY, Lee HK, Yoo JK, Bae K
and Seong YH: Protective effect of Ilex latifolia, a major
component of ‘kudingcha’, against transient focal ischemia-induced
neuronal damage in rats. J Ethnopharmacol. 133:558–564. 2011.
|
|
19
|
Liu L, Sun Y, Laura T, Liang X, Ye H and
Zeng X: Determination of polyphenolic content and antioxidant
activity of Kudingcha made from Ilex kudingcha C.J. Tseng.
Food Chem. 112:35–41. 2009. View Article : Google Scholar
|
|
20
|
Azuma YT, Nishiyama K, Matsuo Y, Kuwamura
M, Morioka A, Nakajima H and Takeuchi T: PPARα contributes to
colonic protection in mice with DSS-induced colitis. Int
Immunopharmacol. 10:1261–1267. 2010.
|
|
21
|
Shin VY, Liu ES, Koo MW, Wang JY, Matsui H
and Cho CH: Cigarette smoke extracts delay wound healing in the
stomach: involvement of polyamine synthesis. Exp Biol Med
(Maywood). 227:114–124. 2002.PubMed/NCBI
|
|
22
|
Gan XL, Hei ZQ, Huang HQ, Chen LX, Li SR
and Cai J: Effect of Astragalus membranaceus injection on
the activity of the intestinal mucosal mast cells after hemorrhagic
shock-reperfusion in rats. Chin Med J (Engl). 119:1892–1898.
2006.
|
|
23
|
Ellman GL: Tissue sulfhydryl groups. Arch
Biochem Biophys. 82:70–77. 1959. View Article : Google Scholar
|
|
24
|
Strober W, Fuss IJ and Blumberg RS: The
immunology of mucosal models of inflammation. Annu Rev Immunol.
20:495–549. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hendrickson BA, Gokhale R and Cho JH:
Clinical aspects and pathophysiology of inflammatory bowel disease.
Clin Microbiol Rev. 15:79–94. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamamki K, Kim DH, Ryu N, Kim YP, Shin KH
and Ohuchi K: Effects of naturally occurring isoflavones on
prostaglandin E2 production. Planta Med. 68:97–100. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cosnes J, Gower-Rousseau C, Seksik P and
Cortot A: Epidemiology and natural history of inflammatory bowel
diseases. Gastroenterology. 140:1785–1794. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chung HL, Yue GG, To KF, Su YL, Huang Y
and Ko WH: Effect of Scutellariae Radix extract on experimental
dextran-sulfate sodium-induced colitis in rats. World J
Gastroenterol. 13:5605–5611. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Langmead L, Dawson C, Hawkins C, Banna N,
Loo S and Rampton DS: Antioxidant effects of herbal therapies used
by patients with inflammatory bowel disease: an in vitro study.
Aliment Pharmacol Ther. 16:197–205. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Malle E, Furtmüller P, Sattler W and
Obinger C: Myeloperoxidase: a target for new drug development? Br J
Pharmacol. 152:838–854. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Babbs CF: Oxygen radicals in ulcerative
colitis. Free Radic Biol Med. 13:169–181. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Holma R, Salmenperä P, Riutta A, Virtanen
I, Korpela R and Vapaatalo H: Acute effects of the
cys-leukotriene-1 receptor antagonist, montelukast, on experimental
colitis in rats. Eur J Pharmacol. 429:309–318. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mustafa A, EI-Medany A, Hagar HH and
EI-Medany G: Ginkgo biloba attenuates mucosal damage in a
rat model of ulcerative colitis. Pharmacol Res. 53:324–330. 2006.
View Article : Google Scholar
|
|
34
|
Osman N, Adawi D, Ahrné S, Jeppsson B and
Molin G: Probiotics and blueberry attenuate the severity of dextran
sulfate sodium (DSS)-induced colitis. Dig Dis Sci. 53:2464–2473.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fiocchi C: Inflammatory bowel disease: new
insights into mechanisms of inflammation and increasingly
customized approaches to diagnosis and therapy. Curr Opin
Gastroenterol. 20:309–310. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dieleman LA, Palmen MJ, Akol H, Bloemena
E, Peña AS, Meuwissen SG and Van Rees EP: Chronic experimental
colitis induced by dextran sulphate sodium (DSS) is characterized
by Th1 and Th2 cytokines. Clin Exp Immunol. 114:385–391. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bai A and Peng Z: Biological therapies of
inflammatory bowel disease. Immunotherapy. 2:727–742. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Perrier C and Rutgeerts P: Cytokine
blockade in inflammatory bowel diseases. Immunotherapy.
3:1341–1352. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rutgeerts P, Sandborn WJ, Feagan BG,
Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer
SB, Lichtenstein GR, et al: Infliximab for induction and
maintenance therapy for ulcerative colitis. N Engl J Med.
353:2462–2476. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Duca I, Ramírez de la Piscina P, Estrada
S, Calderón R, Spicakova K, Urtasun L, Marra-López C, Zabaleta S,
Bengoa R, Marcaide MA and García-Campos F: Steroid-refractory
ulcerative colitis and associated primary sclerosing cholangitis
treated with infliximab. World J Gastroenterol. 19:590–593. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Siegmund B, Lehr HA, Fantuzzi G and
Dinarello CA: IL-1 beta-converting enzyme (caspase-1) in intestinal
inflammation. Proc Natl Acad Sci USA. 98:13249–13254. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tountas NA, Casini-Raggi V, Yang H, Di
Giovine FS, Vecchi M, Kam L, Melani L, Pizarro TT, Rotter JI and
Cominelli F: Functional and ethnic association of allele 2 of the
interleukin-1 receptor antagonist gene in ulcerative colitis.
Gastroenterology. 117:806–813. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dionne S, D’Agata ID, Hiscott J, Vanounou
T and Seidman EG: Colonic explant production of IL-1 and its
receptor antagonist is imbalanced in inflammatory bowel disease
(IBD). Clin Exp Immunol. 112:435–442. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kwon KH, Murakami A, Hayashi R and
Ohigashi H: Interleukin-1beta targets interleukin-6 in progressing
dextran sulfate sodium-induced experimental colitis. Biochem
Biophys Res Commun. 337:647–654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Papadakis KA and Targan SR: Role of
cytokines in the pathogenesis of inflammatory bowel disease. Annu
Rev Med. 51:289–298. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dudhgaonkar S, Tandan SK, Kumar D,
Raviprakash V and Kataria M: Influence of simultaneous inhibition
of cyclooxygenase-2 and inducible nitric oxide synthase in
experimental colitis in rats. Inflammopharmacology. 15:188–195.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cross RK and Wilson KT: Nitric oxide in
inflammatory bowel disease. Inflamm Bowel Dis. 9:179–189. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Martín A, Villegas I and Alarcón de la
Lastra C: The COX-2 inhibitor, rofecoxib, ameliorates dextran
sulphate sodium induced colitis in mice. Inflamm Res. 54:145–151.
2005.PubMed/NCBI
|
|
49
|
Tanaka K, Suemasu S, Ishihara T, Tasaka Y,
Arai Y and Mizushima T: Inhibition of both COX-1 and COX-2 and
resulting decrease in the level of prostaglandins E2 is responsible
for non-steroidal anti-inflammatory drug (NSAID)-dependent
exacerbation of colitis. Eur J Pharmacol. 603:120–132. 2009.
View Article : Google Scholar : PubMed/NCBI
|
